Your browser doesn't support javascript.
loading
Early results on the use of chitosan-N-acetylcysteine (Lacrimera®) in the management of dry eye disease of varied etiology.
Messina, Marco; Dua, Harminder S.
Affiliation
  • Messina M; Section of Academic Ophthalmology, Division of Clinical Neuroscience, Department of Ophthalmology, Queens Medical Centre, Nottingham University Hospitals NHS Trust, University of Nottingham, Derby Road, Nottingham, NG7 2UH, UK.
  • Dua HS; Section of Academic Ophthalmology, Division of Clinical Neuroscience, Department of Ophthalmology, Queens Medical Centre, Nottingham University Hospitals NHS Trust, University of Nottingham, Derby Road, Nottingham, NG7 2UH, UK. harminder.dua@nottingham.ac.uk.
Int Ophthalmol ; 39(3): 693-696, 2019 Mar.
Article in En | MEDLINE | ID: mdl-29549486

Full text: 1 Database: MEDLINE Main subject: Acetylcysteine / Dry Eye Syndromes / Chitosan / Keratitis Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article

Full text: 1 Database: MEDLINE Main subject: Acetylcysteine / Dry Eye Syndromes / Chitosan / Keratitis Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article